^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    RNA splicing modulator

    Related drugs:
    7d
    ABX464-103: Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P2, N=355, Completed, Abivax S.A. | Phase classification: P2b --> P2 | N=254 --> 355
    Phase classification • Enrollment change
    |
    mercaptopurine
    14d
    An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) (clinicaltrials.gov)
    P2, N=144, Active, not recruiting, Novartis Pharmaceuticals | Enrolling by invitation --> Active, not recruiting | N=250 --> 144 | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jun 2027 --> Jul 2029
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    18d
    Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=40, Completed, Abivax S.A. | Phase classification: P2a --> P2
    Phase classification
    1m
    ABTECT - Maintenance (clinicaltrials.gov)
    P3, N=1116, Active, not recruiting, Abivax S.A. | Recruiting --> Active, not recruiting | Trial completion date: Jan 2030 --> May 2030 | Trial primary completion date: Jan 2026 --> Apr 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    3ms
    A Phase I Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect of Food on the Bioavailability of SKY-0515 in Healthy Volunteers and Patients with Huntington’s Disease (ACTRN12624000602527)
    P1, N=50, Completed, Skyhawk Therapeutics, Inc | Recruiting --> Completed
    Trial completion
    3ms
    ABX464-108: Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis (clinicaltrials.gov)
    P2, N=203, Active, not recruiting, Abivax S.A. | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Feb 2027 --> Mar 2026
    Trial completion date • Trial primary completion date
    4ms
    ABX464-105: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 (clinicaltrials.gov)
    P3, N=639, Completed, Abivax S.A. | Recruiting --> Completed | Trial primary completion date: Mar 2025 --> Jun 2025
    Trial completion • Trial primary completion date
    4ms
    ABX464-106: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 (clinicaltrials.gov)
    P3, N=636, Completed, Abivax S.A. | Recruiting --> Completed | Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
    Trial completion • Trial completion date • Trial primary completion date
    5ms
    Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease (clinicaltrials.gov)
    P2/3, N=120, Recruiting, Skyhawk Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    An Open-Label, Crossover, Relative Bioavailability Study Comparing Tablet and Capsule Formulations of SKY-0515 in Healthy Volunteers (ACTRN12625000082404)
    P1, N=16, Completed, Skyhawk Therapeutics, Inc. | Not yet recruiting --> Completed
    Trial completion
    7ms
    Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P2, N=217, Completed, Abivax S.A. | Active, not recruiting --> Completed | Phase classification: P2b --> P2
    Trial completion • Phase classification
    9ms
    Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants with Huntington's Disease (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Skyhawk Therapeutics, Inc.
    New P2/3 trial